Experts Optimistic About SERD Development in HR-Positive Breast Cancer
Emerging selective estrogen receptor degraders (SERDs) offer promising targeted treatment options for early-stage hormone receptor-positive breast cancer, potentially improving survival rates and patient quality of life.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.